Figure 7.
The triple combination of DC vaccination, CpG and anti-CD38 mAb treatment inhibited LLC1 tumor growth. (A) C57BL/6 mice were divided into five groups (five mice per group): (1) 30μg CpG treatment; (2) CpG plus 250μg anti-CD38 mAb; (3) 1×106 L82 LP-pulsed DC vaccination with CpG; (4) the triple combination of L82 LP-pulsed DC vaccination, CpG, and anti-CD38 mAb; and (5) the quadruple combination of DC, CpG, anti-CD38 mAb, and 200μg of anti-PD-1 mAb. LLC1 cells (5 × 105) were subcutaneously inoculated and tumor growth was monitored. (B) On day 14, tumor-infiltrating cells were extracted from these mice (n = 5) and subjected to flow cytometry. * p < 0.05, ** p < 0.01, *** p < 0.001.